Fig. 2
From: Treatment of ErbB2 breast cancer by mitochondrial targeting
Growth inhibition of ErbB2 breast cancer cells by MEDICA. a–d Human ErbB2 AU565and BT474 cells, mouse ErbB2 RH2111 cells, and non-tumorigenic MCF10 cells were treated with MEDICA as indicated. a Cell growth. Mean ± SD. b Anchorage-dependent colonies. c Anchorage-independent colonies. d BT474 spheroids were allowed to form for 24 h followed by treatment for 8 days with MEDICA. Medium was refreshed every 3 days. Spheroid viability assayed by acid phosphatase was inhibited by 90% at 175 μM MEDICA. e Growth (72 h) inhibition of trastuzumab-resistant ErbB2 BT474 cells by MEDICA (left). Resistance was confirmed by growth with increasing trastuzumab concentrations as indicated (right). Mean ± SD. *Significant as compared to control (P < 0.05). f Cell cycle (24 h) suppression of AU565 cells by 200uM MEDICA. Mean ± SD. *Significant as compared to control (P < 0.05). Inset—representative micrographs